Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 467.4% | 48.6% | 5.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 50.5% | -130.6% | -218.6% | -204% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 30.8% | -179.1% | -287.1% | -258.6% |
| EPS Diluted | 0.85 | -0.91 | -0.98 | -0.84 |
| % Growth | 193.4% | 7.1% | -16.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |